Publication & Citation Trends
Most Cited Works
Publications
72 total
Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer.
Cited by 0
Semantic Scholar
AUTX-703, A Novel and Potent KAT2A and KAT2B Proteint Degrader, Induces Profound and Persistent Cell State Differentiation and Inhibits Growth in SCLC Model Systems
Cited by 0
Semantic Scholar
Abstract 903: AURIGIN: A comprehensive single-cell OMICs atlas of human development and an AI/ML framework to classify and identify the drivers of tumor plasticity and altered cellular state
Cited by 0
Semantic Scholar
94 (PB082): AUTX-703, a novel and potent KAT2A and KAT2B protein degrader, induces profound cell state changes and inhibits growth in Small Cell Lung Cancer (SCLC) model systems
Cited by 0
Semantic Scholar
Abstract 5795: Potent and selective degradation of KAT2A and KAT2B induces profound cell state changes and inhibits growth of AML, SCLC and NEPC model systems
Cited by 1
Semantic Scholar
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds PDF
Cited by 47
OpenAlex
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
Cited by 144
OpenAlex
Research Topics
Cancer Immunotherapy and Biomarkers
(34)
Immune cells in cancer
(16)
CAR-T cell therapy research
(14)
Fibroblast Growth Factor Research
(8)
Monoclonal and Polyclonal Antibodies Research
(7)
Frequent Co-Authors
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States)
University of Wisconsin–Madison
Pathways Behavioral Services
Agios Pharmaceuticals (United States)
Quantitative BioSciences